Thrivent Financial for Lutherans Makes New Investment in TransMedics Group, Inc. (NASDAQ:TMDX)

Thrivent Financial for Lutherans purchased a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the 3rd quarter, Holdings Channel.com reports. The institutional investor purchased 26,196 shares of the company’s stock, valued at approximately $4,113,000.

Several other large investors have also recently modified their holdings of TMDX. International Assets Investment Management LLC purchased a new position in TransMedics Group in the second quarter worth about $47,000. USA Financial Formulas bought a new position in TransMedics Group in the 3rd quarter valued at approximately $55,000. J.Safra Asset Management Corp boosted its stake in TransMedics Group by 649.2% during the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after purchasing an additional 383 shares during the last quarter. Signaturefd LLC boosted its position in TransMedics Group by 26.6% in the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after purchasing an additional 93 shares during the last quarter. Finally, Farther Finance Advisors LLC raised its stake in TransMedics Group by 187.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after purchasing an additional 316 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Trading Down 4.2 %

Shares of TMDX opened at $76.04 on Monday. TransMedics Group, Inc. has a twelve month low of $67.77 and a twelve month high of $177.37. The firm has a market capitalization of $2.55 billion, a P/E ratio of 80.89 and a beta of 2.08. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The stock’s fifty day simple moving average is $119.18 and its 200 day simple moving average is $137.77.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. During the same period in the prior year, the firm earned ($0.12) earnings per share. The business’s revenue for the quarter was up 63.7% on a year-over-year basis. On average, equities research analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insider Buying and Selling at TransMedics Group

In related news, insider Nicholas Corcoran sold 10,000 shares of the business’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total value of $1,760,200.00. Following the transaction, the insider now owns 21,105 shares in the company, valued at approximately $3,714,902.10. The trade was a 32.15 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Tamer I. Khayal sold 2,958 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total value of $438,493.92. Following the sale, the insider now owns 20,843 shares of the company’s stock, valued at approximately $3,089,766.32. This trade represents a 12.43 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 36,958 shares of company stock valued at $5,230,528 over the last ninety days. Corporate insiders own 7.00% of the company’s stock.

Wall Street Analysts Forecast Growth

TMDX has been the topic of a number of recent analyst reports. TD Cowen reduced their target price on TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. JPMorgan Chase & Co. lowered their price target on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 29th. Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. Canaccord Genuity Group lowered their price objective on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. Finally, Piper Sandler dropped their price objective on TransMedics Group from $180.00 to $110.00 and set an “overweight” rating on the stock in a report on Wednesday, November 20th. Two analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, TransMedics Group presently has an average rating of “Moderate Buy” and an average target price of $131.80.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.